Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
88
resultados
Última actualización
09/10/2026 [07:06:00]
Resumen de: EP4818164A1
0001 The present invention relates to an indole derivative of formula (I)
3,3'-(pyridine-3,5-diylbis(5-methoxy-1H-indole-2,1-diyl))bis(N,N-dimethylpropan-1-amine) as inhibitors of interaction between Spike and ACE2 proteins for the treatment of infections due to respiratory viruses, such as e.g. SARS-CoV-1, SARS-CoV-2 or MERS CoV infections.
Resumen de: EP4817612A2
0001 Provided is application of a poly ADP ribose polymerase inhibitor or a pharmaceutically acceptable salt thereof in the preparation of antiviral agents or in the preparation of medicines for the treatment of diseases caused by viruses, wherein the viruses are β-coronavirus viruses. Also provided is application of a compound represented by formula III and/or a compound represented by formula IV or a pharmaceutically acceptable salt thereof in the preparation of antiviral agents or in the preparation of medicines for treatment of diseases caused by viruses, the viruses being HIV, HPV, EBV, IFV and/or coronaviruses. The poly ADP ribose polymerase inhibitor comprises a compound represented by formula III and/or a compound represented by formula IV or a pharmaceutically acceptable salt thereof, and can achieve a lower effective concentration for inhibiting viruses and a higher antiviral activity while ensuring low toxicity and high safety when being used in human bodies, so that in the application to the clinical treatment of diseases caused by coronaviruses, the present inhibitor can effectively inhibiting the viruses.
Resumen de: AU2026230128A1
Abstract Provided herein are methods and compositions for the treatment and/or prevention of COVID-19 through the induction of an immune response against identified SARS-COV 2 immunodominant peptides. Abstract
Resumen de: WO2026207328A1
A combined multi-antigen utilizing an immunogenic vector expressing a modified SARS-CoV-2 virus S, M and N protein S-C5 (Delta or Omicron), M-C5, and N-C5, epitopes thereof, compositions comprising same, and methods of use for general vaccination against SARS-CoV-2 virus.
Resumen de: US20260295031A1
0000 The disclosure provides a composition comprising a feline coronavirus (FCoV) receptor binding domain peptide and a human severe acute respiratory syndrome coronavirus serotype 2 (SCoV2) receptor domain peptide and uses thereof.
Resumen de: US20260294902A1
0000 A nanosystem and methods of treating, including prophylactically, coronavirus infections, such as those caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by administering such nanosystem to a patient is presented. The nanosystem may be comprised of a single or a combination of therapeutic agents, optionally encapsulated in a nanoparticle having a targeting moiety directed to the particular coronavirus. For CoV-2 infections, at least one therapeutic agent, such as the dual DPP4/ACE2 inhibitor sitagliptin, may optionally be encapsulated within a nanoparticle having a fatty acid such as linoleic acid, as the targeting moiety. Administration can occur intranasally prior to infection for prophylactic treatment or post-infection for treatment of the viral infection.
Resumen de: US20260297692A1
The present invention discloses a probe set for nucleic acid testing of SARS-CoV-2 coronaviruses and uses. A crRNA sequence for nucleic acid testing of SARS-CoV-2 coronaviruses is any one of the following: LbucrRNA1, LbucrRNA2, LbucrRNA3 and LbucrRNA4 for an S gene, as well as N1crRNA and N2crRNA for an N gene of a mutant strain EG.5.1.1, with sequences shown in the sequence listing. Based on the ability of the LbuCas13a protein to cleave free RNAs and target specific RNA sequences, the present invention establishes an Cas13a-based immunochromatographic method for nucleic acid testing using a visual testing method based on colloidal carbon immunochromatographic test strips. The method enables rapid testing of SARS-CoV-2 coronaviruses within 90 min, providing a novel, easy and rapid testing method for disease prevention and control. Moreover, the method is simple to operate and does not require the assistance of large instruments and equipment.
Resumen de: US20260295033A1
An immunogenic composition is described, comprising mRNA encoding polypeptides constituting a virus-like particle (VLP), and a pharmaceutically acceptable carrier. The polypeptides constituting the VLP comprise: a first polypeptide comprising a gag protein found in murine leukemia virus (MEV) having at least 95% identity with the amino acid sequence of SEQ ID NO: 1; and at least one additional polypeptide, which may comprise a protein of a virus, such as EB V, CMV, or coronavirus, for example a spike glycoprotein from a beta coronavirus such as SARS-COV-2, SARS-COV-1 or MERS-COV; or the at least one additional polypeptide may comprise a protein expressed by a cancer cell or tumour cell. A lipid nanoparticle composition is also described, which may comprise the VLPs. Methods of treatment or prevention of infection, such as from EBV, CMV, or coronavirus, or for treatment or prevention of cancer are described.
Resumen de: EP4814118A1
0001 The present invention discloses a VZV antigen variant, a nucleic acid, a pharmaceutical composition, and uses thereof. The VZV antigen variant has a Y582G difference compared to the amino acid sequence shown in SEQ ID NO: 1; and/or, the VZV antigen variant has a deletion of positions 561-623, 569-623, or 574-623 compared to the amino acid sequence shown in SEQ ID NO: 1; and/or, the VZV antigen variant has a modification of the protein transmembrane domain and intracellular domain compared to the amino acid sequence shown in SEQ ID NO: 1, wherein the modification of the protein transmembrane domain and intracellular domain comprises replacing the transmembrane domain and intracellular domain of the original VZV antigen with the transmembrane domain of the SARS-CoV-2 Spike protein or the transmembrane domain of the influenza H protein. The VZV antigen variant has stronger immunogenicity than VZV antigens in the prior art, can achieve higher binding antibody titers, and has higher protective efficacy.
Resumen de: WO2025111412A1
Small anti-inflammatory peptide for blocking NF-κB are disclosed herein. The peptides as well as compositions including the peptides can be administered to inhibit cytokine production and/or inhibit pulmonary inflammation in a subject in need. Particularly embodiments include administration to a subject suffering from coronavirus disease 2019 (COVID-19).
Resumen de: US20260284056A1
Disclosed herein are methods for the treatment of cancer and inflammatory-based diseases and disorders, such as coronavirus colds and as a therapy against COVID-19. ImmunoFolate has been shown to reduce the incidents of colds and flus. In one embodiment is a method of treating cancer comprising administration of ImmunoFolate. In another embodiment is a method of treatment inflammatory-based disease and disorders comprising administration of ImmunoFolate.
Resumen de: US20260284083A1
The present invention relates to the use of antagonists of tlr7-signalling for the treatment of COVID-19 patients, wherein the antagonists of tlr7-signalling are administered only after serovonversion. The invention also relates to a tlr agonist for use in the one-time prophylactic treatment of a subpopulation against an infection with a coronavirus, wherein the subpopulation is a collection of asymptomatic subjects in proximity to subjects of the population who show symptoms of infection.
Resumen de: US20260283946A1
The present invention provides a pharmaceutical dry powder composition for use in treating, preventing and/or amelio-rating viral infection in airways of a mammal, such as a human subject, said composition comprising micronized sodium salt as the main component and primary therapeutic agent. The present invention further provides a pharmaceutical composition for use in treating and/or ameliorating cough. The subject to be treated with the pharmaceutical composition may be infected with SARS-COV-2 and/or diagnosed with COVID-19 infection. The pharmaceutical composition is administered by dry powder inhalation.
Resumen de: US20260284181A1
0000 The present invention provides a viral vector comprising, at an insertion site in the viral genome, a nucleic acid sequence encoding a modified extracellular domain of the SARS-CoV-2 spike protein, wherein said modified extracellular domain comprises an N-terminal signal peptide causing the spike protein to enter a secretory system in a host cell, wherein said modified extracellular domain comprises a C-terminal deletion of at least of heptad repeat 2 (HR2), transmembrane segment (TM) and cytoplasmic tail (CT) of the spike protein. The present invention also provides a vaccination composition comprising said viral vector.
Resumen de: US20260283984A1
Methods for treating coronavirus disease 2019 (COVID-19), including at least one ocular manifestation of COVID-19, methods for treating conjunctivitis, and methods for reducing COVID-19 transmission comprising administering an effective amount of benzalkonium chloride are disclosed. Pharmaceutical compositions comprising benzalkonium chloride are also disclosed.
Resumen de: US20260284187A1
0000 Provided herein are adjuvantation systems comprising mannan (e.g., a plant mannan or a fungal manna) for use with Beta coronavirus (e.g., MERS-CoV, SARS-CoV-1, or SARS-CoV-2) vaccines and immunogenic compositions comprising the adjuvantation system and a Beta coronavirus antigen or a nucleic acid encoding the Beta coronavirus antigen.
Resumen de: WO2026197674A1
The present invention relates to a replication-deficient SARS-CoV-2 vaccine strain comprising a mutation in the N gene and uses thereof. More specifically, the present invention relates to a SARS-CoV-2 vaccine strain having five stop codons inserted into the N (nucleocapsid) gene of SARS-CoV-2, such that replication is impossible in cells in which the N gene is not trans-complemented, and uses thereof.
Resumen de: EP4810599A2
0001 The invention is directed to a method of treating viral-induced acute respiratory distress syndrome (ARDS) by administering to a subject with the virial induced ARDS multipotent adult progenitor cells (MAPCs), which are non-embryonic stem, non-germ cells that have a broad differentiation potential and extended replication capacity. The virus inducing the ARDS can be a Betacoronavirus, such as, severe acute respiratory syndrome (SARS), Corona Virus or Middle East Respiratory Syndrome (MERS), or severe acute respiratory syndrome Corona Virus 2 (SARS-CoV-2).
Resumen de: EP4810861A2
An apparatus is used with supplied power for treating air in an environment. A housing is mobile in the environment and has an intake and an exhaust. At least one prime mover disposed in the housing between the intake and the exhaust is operable to move the air in the environment through the housing from the intake to the exhaust. At least one ultraviolet light source disposed in the housing is connected in electrical communication with the supplied power and is configured to generate ultraviolet radiation in at least one a portion of the housing through which the moved air passes from the intake to the exhaust. At least one permeable barrier disposed in the housing is configured to impede the moved air flow therethrough up to an impedance threshold. The at least one permeable barrier is connected in electrical communication to the supplied power and being heated to a surface temperature.
Resumen de: US20260274133A1
Disclosed herein are systems for minimizing the risk of transmission of SARS-COV-2 and/or other infectious diseases between individuals in close proximity to one another. Said systems may comprise a substantially transparent shield component, a chamber component, and a suctioning component. The systems of the present disclosure are intended to remove any SARS-COV-2 virus and/or other infectious agents that may be travelling within aerosols.
Resumen de: WO2026193026A1
The invention provides methods for determining if a subject suffering from SARS-CoV-2 infection is susceptible to developing fibromyalgia. Also provided herein are methods for identifying if a subject possesses a disease or condition characterized or caused by an immune system deficiency, such as chronic pain or fatigue, long COVID or interstitial cystitis (IC).
Resumen de: AU2025231994A1
The present invention relates to second-generation vaccine against COVID-19 to abrogate or diminish the binding of the SARS-CoV-2 spike (S) protein, or part of it, to the human angiotensin-converting enzyme 2 (hACE2). Such vaccines present several advantages as to avoid pathways of immune dysregulation activated following S protein/hACE2 interaction while maintaining the ability to elicit a strong and robust antibody neutralization response to SARS-CoV-2. The invention relates also to the use of the S protein for therapeutic uses and for vaccines in the prevention or treatment of SARS-CoV-2 infection or conditions or disorders resulting from such infection.
Resumen de: WO2026192998A1
A peptide that blocks the interaction of microtubule-associated factor End Binding protein 3 with inositol 1, 4, 5-trisphosphate receptor 3 and calcium release from the endoplasmic reticulum, and methods of using the peptide to treat a disease or condition, in particular an inflammatory disease or condition of the lung including sepsis, inflammatory lung injury, pulmonary fibrosis, acute respiratory distress syndrome, or SARS-CoV-2 infection.
Resumen de: US20260272861A1
Provided herein are methods for the treatment, mitigation, and prevention of viral infections (e.g., coronavirus infections (e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etc.), etc.) and diseases (e.g., Coronavirus disease 2019 (COVID-19)) associated therewith by the administration of cysteamine or derivatives thereof to a subject.
Nº publicación: PL4240328T3 14/09/2026
Solicitante:
ACELLMED SP Z O O [PL]
Acellmed Sp. z o.o.
Resumen de: WO2022098250A1
An object of the invention is a liposome preparation suitable for use in the treatment of COVID-19.
BOPI
Sede Electrónica
